- Home
- CRDF vs MTLS Comparison
CRDF vs MTLS Comparison
Compare CRDF & MTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- MTLS
- Stock Information
- Founded
- CRDF 1999
- MTLS 1990
- Country
- CRDF United States
- MTLS Belgium
- Employees
- CRDF N/A
- MTLS N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- MTLS Computer Software: Prepackaged Software
- Sector
- CRDF Health Care
- MTLS Technology
- Exchange
- CRDF Nasdaq
- MTLS Nasdaq
- Market Cap
- CRDF 196.2M
- MTLS N/A
- IPO Year
- CRDF N/A
- MTLS 2014
- Fundamental
- Price
- CRDF $2.63
- MTLS $5.51
- Analyst Decision
- CRDF Strong Buy
- MTLS
- Analyst Count
- CRDF 4
- MTLS 0
- Target Price
- CRDF $12.00
- MTLS N/A
- AVG Volume (30 Days)
- CRDF 1.1M
- MTLS 131.3K
- Earning Date
- CRDF 05-20-2025
- MTLS 04-24-2025
- Dividend Yield
- CRDF N/A
- MTLS N/A
- EPS Growth
- CRDF N/A
- MTLS 43.31
- EPS
- CRDF N/A
- MTLS 0.17
- Revenue
- CRDF $683,000.00
- MTLS $291,295,936.00
- Revenue This Year
- CRDF N/A
- MTLS $6.55
- Revenue Next Year
- CRDF N/A
- MTLS $9.21
- P/E Ratio
- CRDF N/A
- MTLS $30.75
- Revenue Growth
- CRDF 39.96
- MTLS 6.16
- 52 Week Low
- CRDF $2.01
- MTLS $3.93
- 52 Week High
- CRDF $5.64
- MTLS $9.69
- Technical
- Relative Strength Index (RSI)
- CRDF 41.22
- MTLS 63.19
- Support Level
- CRDF $2.42
- MTLS $5.21
- Resistance Level
- CRDF $2.87
- MTLS $5.43
- Average True Range (ATR)
- CRDF 0.18
- MTLS 0.20
- MACD
- CRDF 0.01
- MTLS 0.09
- Stochastic Oscillator
- CRDF 24.42
- MTLS 93.39
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.